![Mark S. Cohen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark S. Cohen
Voorzitter bij Tarus Therapeutics, Inc.
Actieve functies van Mark S. Cohen
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Tarus Therapeutics, Inc.
![]() Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Voorzitter | 01-01-2021 | - |
Life Sciences Practice Group | Voorzitter | - | - |
Loopbaan van Mark S. Cohen
Eerdere bekende functies van Mark S. Cohen
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AKARI THERAPEUTICS, PLC | Directeur/Bestuurslid | - | 14-10-2016 |
Independent Dir/Board Member | - | 14-10-2016 | |
Pearl Cohen Zedek Latzer LLP | Oprichter | 01-01-1999 | 26-07-2013 |
Corporate Officer/Principal | 05-07-2012 | 26-07-2013 | |
Catalent MSTC, Inc.
![]() Catalent MSTC, Inc. Medical SpecialtiesHealth Technology Catalent MSTC, Inc. provides full service contract development and manufacturing services (CDMO) for cell therapy companies. It offers process and assay development, quality management, and cGMP cell therapy manufacturing services. The company was incorporated on December 27, 2017 and is headquartered in Dover, DE. | Directeur/Bestuurslid | - | - |
Celsus Therapeutics Plc
![]() Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Voorzitter | 07-09-2011 | - |
Opleiding van Mark S. Cohen
Rutgers State University of New Jersey | Undergraduate Degree |
New York University | Graduate Degree |
University of Baltimore School of Law | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Verenigd Koninkrijk | 2 |
Frankrijk | 2 |
Operationeel
Chairman | 3 |
Graduate Degree | 2 |
Director/Board Member | 2 |
Sectoraal
Health Technology | 5 |
Consumer Services | 4 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AKARI THERAPEUTICS, PLC | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Celsus Therapeutics Plc
![]() Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Pearl Cohen Zedek Latzer LLP | Commercial Services |
Tarus Therapeutics, Inc.
![]() Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Health Technology |
Catalent MSTC, Inc.
![]() Catalent MSTC, Inc. Medical SpecialtiesHealth Technology Catalent MSTC, Inc. provides full service contract development and manufacturing services (CDMO) for cell therapy companies. It offers process and assay development, quality management, and cGMP cell therapy manufacturing services. The company was incorporated on December 27, 2017 and is headquartered in Dover, DE. | Health Technology |
Life Sciences Practice Group |
- Beurs
- Insiders
- Mark S. Cohen
- Ervaring